Lung Cancer Surgery — VATS, Robotic & Lobectomy

VATS stands for video-assisted thoracic surgery — a minimally invasive (keyhole) operation for lung cancer. Instead of a large open-chest incision, the surgeon makes 2 to 3 small cuts between the ribs and uses a thin camera (thoracoscope) and long instruments to remove the affected part of the lung, most commonly a whole lobe (VATS lobectomy), along with the chest lymph nodes. Because the ribs are not spread apart, VATS causes less post-operative pain, a shorter hospital stay (typically 2 to 4 days), and a faster recovery than open surgery — while removing the same cancer.

A lobectomy is the surgical removal of one lobe of the lung — the lobe that contains the tumour — together with the lymph nodes that drain it. The right lung has three lobes and the left lung has two. Lobectomy is the standard, most-studied operation for fit patients with early-stage (Stage I and II) non-small cell lung cancer, and it offers the best chance of cure. It can be performed by minimally invasive VATS, by robotic surgery, or by open surgery, depending on the size and position of the tumour. Most people manage well with one fewer lobe, as the remaining lung tissue compensates over time.

Robotic lung surgery (robotic-assisted thoracic surgery) is another minimally invasive approach. The surgeon sits at a console and controls robotic arms that hold the camera and instruments, working through small keyhole ports. It provides a magnified 3D high-definition view and wristed instruments that move with great precision and filter out hand tremor — which can help when dissecting close to blood vessels and lymph nodes. Both robotic surgery and VATS are minimally invasive and offer less pain and faster recovery than open surgery. The choice between them depends on the tumour location, your anatomy, and the surgical team's expertise; the cancer operation performed is the same.

Surgery is generally recommended for patients with early-stage non-small cell lung cancer (Stage I and II), and for some selected Stage IIIA tumours as part of a combined plan. Two things must be confirmed: that the cancer has not spread beyond what surgery can remove (assessed with CT, PET-CT, and usually EBUS lymph node sampling), and that your lung function and general health allow part of the lung to be removed safely (assessed with lung function tests and a heart evaluation). Surgery is usually not the main treatment for small cell lung cancer or for Stage IV disease. Every case at CION is reviewed by a tumour board before a recommendation is made.

Recovery is generally quicker after minimally invasive surgery than after open surgery. Most patients stay in hospital for 2 to 4 days after a VATS lobectomy, are encouraged to walk within a day of the operation, and have the chest drain removed before going home. Many people return to light daily activities within 2 to 4 weeks, with heavier activity and work resuming gradually after that. Breathing exercises and physiotherapy support your recovery. Recovery time varies with your age, lung function, and general health, so your team will give you guidance specific to your situation.

Yes. For suitable early-stage tumours, minimally invasive VATS and robotic surgery remove the same lobe and sample the same lymph nodes as open surgery — the cancer operation is identical, only the access is smaller. The minimally invasive approach is associated with less pain, fewer wound and chest complications, and faster recovery, without compromising the completeness of cancer removal. For large or centrally located tumours, an open operation may still be the safest choice. The surgeon recommends the approach that allows complete, safe removal of the cancer for your specific tumour.

These operations differ in how much lung is removed. A lobectomy removes the whole lobe containing the tumour and is the standard cancer operation for fit early-stage patients. A segmentectomy removes only an anatomical segment of a lobe, and a wedge resection removes a small wedge of lung around the tumour — both are lung-sparing operations used for very small peripheral tumours (generally under 2 cm) or for patients whose lung function will not allow a whole lobe to be removed. Your surgeon chooses the smallest operation that still removes the cancer completely with a safe margin.

Most people manage well after having a lobe removed, because the remaining lung tissue takes over much of the work and the body adjusts over the following weeks. Before surgery, lung function tests estimate how your breathing will be afterwards, which helps the team decide how much lung can be safely removed. Some patients notice breathlessness on exertion at first, which usually improves with breathing exercises, physiotherapy, and gradual activity. If your lung function is limited, a smaller lung-sparing operation or a non-surgical option such as SBRT may be recommended instead.

Not always. After surgery, the removed lobe and lymph nodes are examined under the microscope to confirm the final stage. For some patients — particularly when lymph nodes contain cancer or the tumour is larger — chemotherapy after surgery (called adjuvant therapy) can lower the chance of the cancer returning. For tumours found to carry an EGFR mutation, targeted tablet therapy after surgery may be recommended. The decision is made together by the surgeon, medical oncologist, and pathologist at the tumour board, based on the final pathology of your specimen.

Cost depends on the operation and the surgical approach. As an indicative guide at CION: VATS lobectomy ₹2,50,000–₹6,00,000; robotic lobectomy ₹3,50,000–₹8,00,000; segmentectomy or wedge resection ₹2,00,000–₹5,00,000; open lobectomy ₹2,00,000–₹5,50,000. Pre-operative work-up, PET-CT staging (₹9,999–₹16,000 through CION's imaging network), and EBUS add to this. Final cost varies with stage, hospital stay, and other medical conditions. A personalised estimate is given after your consultation, and EMI options plus cashless TPA empanelment are available.

Yes, and it is a reasonable step before any cancer operation. A surgical second opinion is particularly valuable if you have been told you need surgery and want to confirm a minimally invasive or lung-sparing option is possible, or if you have been told you are not a candidate for surgery and want to check whether a smaller operation or a non-surgical curative option such as SBRT could help. CION offers a dedicated Second Opinion service where your scans and reports are reviewed by the surgical and medical oncology team together, with no obligation to proceed with treatment.